Abstract
BackgroundLong non‐coding RNAs (lncRNAs), a vital component of functional regulators, are involved in various human cancers development, including diffuse large B‐cell lymphoma (DLBCL). In particular, lncRNA HAGLROS has been reported to be associated with several types of cancer in humans. Nevertheless, the role of HAGLROS in DLBCL has yet to be described.MethodsThe HAGLROS expression patterns and its relationship with clinicopathological features and survival were investigated in DLBCL patients. CCK‐8 and transwell assays were used to analyze the cell proliferation, migration, and invasion capacities. AGO2‐RIP, dual‐luciferase assay, RT‐qPCR, and rescue experiments were fulfilled to measure the physical interaction between HAGLROS and miR‐100. Xenograft assay was conducted to test tumor growth ability.ResultsHAGLROS was upregulated in DLBCL tissues and cells, and closely associated with advanced clinicopathological features. Upregulation of HAGLROS resulted in poor survival outcomes in DLBCL patients. In addition, HAGLROS knockdown inhibited the proliferation, migration, and invasion of DLBCL cells in vitro. Further experiments revealed that HAGLROS negatively regulated the expression of miR‐100 in DLBCL, and the expression of miR‐100 and HAGLROS showed an inverse correlation in DLBCL tissues. HAGLROS functioned as a competing endogenous RNA for miR‐100 in DLBCL cells, and miR‐100 overexpression abolished the oncogenic effects of HAGLROS upregulation on DLBCL progression. Besides, in‐vivo assays revealed that HAGLROS knockdown suppressed tumor growth in nude mice.ConclusionHAGLROS overexpression contributes to DLBCL development and poor prognosis via targeting miR‐100, which could be a potential prognostic biomarker and therapeutic target for DLBCL patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call